Prudential Financial
DSGN icon

Prudential Financial’s Design Therapeutics DSGN Stock Holding History

Prudential Financial’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$487K Buy
45,810
+3,100
+7% +$31.4K ﹤0.01% 1877
2025
Q4 		$401K Sell
42,710
-2,115
-5% -$16.6K ﹤0.01% 1902
2025
Q3 		$338K Sell
44,825
-13,100
-23% -$65.6K ﹤0.01% 2070
2025
Q2 		$195K Buy
57,925
+1,520
+3% +$5.69K ﹤0.01% 2217
2025
Q1 		$218K Buy
56,405
+90
+0.2% +$429 ﹤0.01% 2058
2024
Q4 		$347K Sell
56,315
-2,800
-5% -$16.2K ﹤0.01% 1951
2024
Q3 		$318K Sell
59,115
-4,100
-6% -$19.3K ﹤0.01% 2380
2024
Q2 		$212K Buy
63,215
+16,400
+35% +$63.9K ﹤0.01% 2468
2024
Q1 		$189K Buy
46,815
+28,400
+154% +$75.9K ﹤0.01% 2477
2023
Q4 		$48.8K Hold
18,415
– – ﹤0.01% 2552
2023
Q3 		$43.5K Sell
18,415
-7,800
-30% -$36.4K ﹤0.01% 2514
2023
Q2 		$165K Buy
+26,215
New +$160K ﹤0.01% 2452

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Prudential Financial's DSGN Position: Q1 2026 in Review

Prudential Financial increased its Design Therapeutics (DSGN) stake by 7.3% in Q1 2026, buying an estimated $31.4K and bringing the position to 45,810 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #1877.

Prudential Financial first reported a position in DSGN in Q2 2023 and has held it in 12 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Prudential Financial held 45,810 shares of Design Therapeutics worth $487K as of Q1 2026.
  • Prudential Financial bought 3,100 Design Therapeutics shares in Q1 2026, an estimated $31.4K.
  • Design Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1877 holding.
  • Prudential Financial first reported a position in Design Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.